How much does a box of Fruquintinib cost after reimbursement?

Fruquintinib (Fruquintinib) is an oral small molecule targeted therapy drug that belongs to a class of multicaseokinase inhibitors. It is primarily designed to treat digestive system tumors such as advanced colorectal and gastric cancer. As a targeted therapy, fruquintinib interferes with the process of tumor angiogenesis by inhibiting vascular endothelial growth factor receptors (VEGFR), specifically VEGFR-1, VEGFR-2 and VEGFR-3.

Fruquintinib is a drug developed in Hong Kong, China. It has been approved for marketing by the State Food and Drug Administration and has been included in medical insurance. Patients can buy it in domestic hospital pharmacies at a price of about one to two thousand. For specific prices, please consult the local hospital pharmacy.

Vascular endothelial growth factor (VEGF) is a protein that promotes the formation of new blood vessels, which is critical for tumor growth and spread. Fruquintinib inhibits this process by blocking the activity of VEGFR and reducing the tumor's dependence on the blood supply, thereby hopefully slowing the growth and spread of the tumor.

Fruquintinib is usually used as part of maintenance therapy, which is continued use of fruquintinib to control the disease if the tumor becomes resistant to other treatments or the disease progresses. The goal of this treatment strategy is to prolong patient survival, improve quality of life, and slow disease progression.

In clinical trials, fruquintinib has shown certain efficacy, especially in some patients with advanced colorectal cancer and gastric cancer. However, specific treatment effects will vary depending on individual patient differences, disease characteristics, and other factors. The safety and tolerability of the drug is also one of the important factors when considering treatment options, so patients need close monitoring and physician guidance when using fruquintinib.